ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO1048

Impact of CKD on Patients' Health-Related Quality of Life: Results from PaCE-CKD, a Multinational Survey

Session Information

Category: CKD (Non-Dialysis)

  • 2302 CKD (Non-Dialysis): Clinical, Outcomes, and Trials


  • Garcia Sanchez, Juan Jose, AstraZeneca PLC, Cambridge, United Kingdom
  • Rangaswami, Janani, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, United States
  • Wu, Mai-Szu, Taipei Medical University, Taipei, Taiwan
  • Esposito, Ciro, Universita degli Studi di Pavia, Pavia, Lombardia, Italy
  • Hull, Richard, St George's University Hospitals NHS Foundation Trust, London, United Kingdom
  • Chadban, Steven J., Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
  • Elsayed, Hesham Mohamed, Ain Shams University Faculty of Medicine, Cairo, Egypt
  • Reichel, Helmut, Nephrologisches Zentrum Villingen Schwenningen, Villingen-Schwenningen, Baden-Württemberg, Germany
  • Correa-Rotter, Ricardo, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de Mexico, Ciudad de México, Mexico
  • Pentakota, Surendra, AstraZeneca PLC, Cambridge, United Kingdom
  • West, Bronwyn, CaPPRe: Community and Patient Preference Research, Sydney, New South Wales, Australia
  • Mellor, Richard, CaPPRe: Community and Patient Preference Research, Sydney, New South Wales, Australia
  • Kularatne, Thames, CaPPRe: Community and Patient Preference Research, Sydney, New South Wales, Australia
  • Fifer, Simon, CaPPRe: Community and Patient Preference Research, Sydney, New South Wales, Australia

Chronic kidney disease (CKD) has a substantial burden on patients’ health-related quality of life (HRQoL). The aim of this study was to quantitatively determine the effect of CKD on patient HRQoL from early disease to kidney failure in a multinational setting.


A cross-sectional survey enrolled individuals with CKD in the US, UK, Germany and Mexico. HRQoL was assessed using the EQ-5D-5L instrument, scoring problems in five domains – anxiety/depression, mobility, pain, self-care, and usual activities. EQ-5D index scores were estimated by the inclusion of local tariffs. Scores were compared against a general population cohort, matched in sample size and key demographic characteristics (e.g. sex, age).


Patients were enrolled from the US (n=199), UK (n=212), Germany (n=201) and Mexico (n=204). Inclusion criteria included patients with CKD stages 1-5 and those receiving dialysis. Of patients enrolled, a proportion were dialysis dependent (DD) in the US (32.2%), UK (54.8%), Germany (42.3%) and Mexico (56.9%). Across all countries, patients received haemodialysis more commonly than peritoneal dialysis and the majority were on treatment for less than five years. Patients with CKD had a 28% reduction in mean EQ-5D-5L scores than the general population in all settings. Patients in the UK experienced the lowest EQ-5D scores with a 32% reduction and mean index scores of 0.64 [0.27] versus 0.95 [0.08]. Patients in Mexico and the UK receiving dialysis had lower mean [SD] EQ-5D-5L scores than non-dialysis dependent (NDD) patients (0.66 [0.21] vs 0.74 [0.18]; 0.60 [0.25] vs 0.68 [0.27] respectively). There was no difference in HRQoL between DD and NDD patients in the US and Germany. Patients with CKD had problems in all five EQ-5D domains, with an 88% increase in reporting related to usual activities. Results for other countries will also be presented at Kidney Week.


This survey provides evidence across multiple countries on the HRQoL decrement associated with CKD. Evidence based policy interventions should be aimed towards slowing CKD progression to improve patient quality of life.


  • Commercial Support – AstraZeneca